This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
by Ahan Chakraborty
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
PFENo Net Change TBPHPositive Net Change CRMDPositive Net Change VTRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
by Zacks Equity Research
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
BMYPositive Net Change PFENo Net Change ALKSNegative Net Change BNTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
ALNYNegative Net Change VRTXPositive Net Change ZTSPositive Net Change EXASPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
by Zacks Equity Research
ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth; 2025 guidance raised after strong demand.
ALKSNegative Net Change ANIPNegative Net Change AVDLNegative Net Change HOWLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
GSKPositive Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase
by Zacks Equity Research
Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology earnings medical pharmaceuticals
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte posts strong Q3 results as higher sales of Jakafi, Opzelura and new launches drive revenue and earnings beats.
NVSPositive Net Change LLYPositive Net Change INCYPositive Net Change ANIPNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
by Ahan Chakraborty
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
PFENo Net Change AMPHPositive Net Change CRMDPositive Net Change
biotechnology biotechs hospitals medical pharmaceuticals
EastGroup Properties (EGP)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
EGPPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
RDYPositive Net Change MRKNegative Net Change AMGNPositive Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
by Ahan Chakraborty
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
BMYPositive Net Change MRKNegative Net Change LLYPositive Net Change GILDNegative Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.
BMYPositive Net Change PFENo Net Change BNTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
by Ekta Bagri
Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength
BMYPositive Net Change PFENo Net Change
biotechnology biotechs medical pharmaceuticals
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
NVSPositive Net Change LLYPositive Net Change INCYPositive Net Change EXASPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
by Zacks Equity Research
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
REGNPositive Net Change ALNYNegative Net Change NVSPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
After Golden Cross, Aaon (AAON)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
AAONNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
by Ahan Chakraborty
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
by Zacks Equity Research
Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.
REGNPositive Net Change ALNYNegative Net Change RHHBYPositive Net Change ETNBNo Net Change
biotechnology earnings medical pharmaceuticals
NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board
by Zacks Equity Research
Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.
ALNYNegative Net Change NVONegative Net Change LLYPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
by Ekta Bagri
ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.
BDTXNo Net Change ORICPositive Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Sell Stocks for Oct. 22
by Zacks Equity Research
ATOS, BLIN and CLTP have been added to the Zacks Rank #5 (Strong Sell) List on Oct. 22, 2025.
BLINPositive Net Change ATOSPositive Net Change CTLPNegative Net Change
biotechnology
Allegiant Travel (ALGT) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
ALGTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
by Zacks Equity Research
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
ALNYNegative Net Change RHHBYPositive Net Change ANIPNegative Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients
by Zacks Equity Research
Novo Nordisk secures FDA approval for Rybelsus as the first oral GLP-1 therapy proven to cut major heart risks in adults with type II diabetes.
ALNYNegative Net Change NVONegative Net Change ANIPNegative Net Change CMMBNegative Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Oct 21, 2025
by Zacks Equity Research
Companies in The News Are: SMMT, CLF, LHX, COO
CLFNegative Net Change COOPositive Net Change SMMTNegative Net Change LHXPositive Net Change
biotechnology tech-stocks